Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: Preliminary results of a phase i dose escalation study

Clinical Oncology

Volumn 22, Issue 3, 2010, Pages 236-244

  Guerrero Urbano, T ^a,d   Khoo, V ^a   Staffurth, J ^a,e   Norman, A ^b   Buffa, F ^c   Jackson, A ^a,f   Adams, E ^a,g   Hansen, V ^a   Clark, C ^a   Miles, E ^a,h   McNair, H ^a   Nutting, C ^a   Parker, C ^a   Eeles, R ^a   Huddart, R ^a   Horwich, A ^a   Dearnaley, D P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e VELINDRE CANCER CENTRE   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g Royal Surrey Hospital   (United Kingdom)

^h MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Dose escalation; IMRT; Pelvic lymph nodes; Prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ABNORMAL FECES; ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CYSTITIS; DIARRHEA; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; TREATMENT DURATION; URINE INCONTINENCE;

AGED; GASTROINTESTINAL TRACT; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; UROGENITAL SYSTEM;

EID: 77950027880     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.01.005     Document Type: Article

References (31)

1. Roach M., Lu J., Pilepich M.V., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000, 47:609-615.
2. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106.
3. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
4. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
5. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
6. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
7. Pan C.C., Kim K.Y., Taylor J.M., et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2002, 53:1139-1145.
8. Seaward S.A., Weinberg V., Lewis P., et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1998, 42:1055-1062.
9. Ploysongsang S.S., Aron B.S., Shehata W.M. Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate?. Urology 1992, 40:18-26.
10. Lawton C.A., DeSilvio M., Roach M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69:646-655.
11. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007, 25:5366-5373.
12. Gallagher M.J., Brereton H.D., Rostock R.A., et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986, 12:1565-1573.
13. Letschert J.G., Lebesque J.V., de Boer R.W., et al. Dose-volume correlation in radiation-related late small-bowel complications: a clinical study. Radiother Oncol 1990, 18:307-320.
14. Nutting C., Convery D., Cosgrove V., et al. Reduction in small and large bowel irradiation using an optimised intensity-modulated pelvic radiotherapy technique (IMRT) in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48(3):649-656.
15. Roach M., Marquez C., You H.-S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994, 28:33-37.
16. Staffurth J, Adams E, Breen S, et al. Target volume definition for intensity modulated whole pelvic radiotherapy (IMWPRT), ASCO Prostate Cancer Symposium. Orlando, Florida 17/18 February 2005, abstract no. 185.
17. Adams E.J., Convery D.J., Cosgrove V.P., et al. Clinical implementation of dynamic and step and shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol 2004, 70:1-10.
18. Clark C.H., Mbuata C.D., Meehan C.A., et al. IMRT clinical implementation: prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. J Appl Clin Med Phys 2002, 3:273-284.
19. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003, 57:953-962.
20. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
21. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635-642.
22. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 52:1330-1337.
23. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
24. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92:488-498.
25. Capirci C., Polico C., Mandoliti G. Dislocation of small bowel volume within box pelvic treatment fields, using new 'up down table' device. Int J Radiat Oncol Biol Phys 2001, 51:465-473.
26. Roeske J.C., Bonta D., Mell L.K., et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003, 69:201-207.
27. Baglan K.L., Frazier R.C., Yan D., et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002, 52:176-183.
28. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998, 41:83-92.
29. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:24-33.
30. Dearnaley D, Sumo G, Syndikus I, et al. Initial toxicity results of the phase III conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP) trial (ISRCTN97182923), ASCO Genitourinary Cancers Symposium. Orlando, Florida, USA, 2009.
31. Khoo V.S., Dearnaley D.P. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer-the CHHiP trial. Clin Oncol (R Coll Radiol) 2008, 20:12-14.